METLIFE INCMET
METLIFE INC Financial Overview 2021–2025
Updated Jul 10, 2026MetLife’s net income collapsed from $1.6 billion in Q1 2022 to a mere $14 million in Q1 2023, a sudden plunge that highlights the company's core investment thesis: management offsets severe derivative and investment portfolio volatility through aggressive capital returns and structural de-risking. Reflecting years of strategic run-offs and market friction, total assets contracted from $759.7 billion in FY2021 to $719.7 billion during FY2025. Despite this shrinking footprint, the company's outstanding shares steadily declined from 0.83 billion in FY2021 to 0.69 billion in FY2024, actively propping up equity value even as raw earnings per share fell from $7.65 to $5.94 over the same period.
To further isolate core operations from unhedged market noise, MetLife executed major risk-transfer transactions, highlighted by a $10 billion reinsurance agreement with Chariot Reinsurance in 2025 to cede legacy annuity reserves. While quarterly GAAP results remained highly vulnerable to interest rate swings—such as a $1.7 billion net derivative loss in Q3 2025—underlying business performance proved resilient, with adjusted earnings holding firm at $1.6 billion that same quarter. Strategic acquisitions also diversified the revenue base, culminating in the purchase of PineBridge Investments in 2025 to significantly expand its asset management segment. The market rewarded this combination of balance sheet optimization and share reduction, valuing the stock at a close of $78.94 at the end of FY2025.
Recent Developments (Q4 2025 and Q1 2026)
MetLife carried strong operational momentum into 2026, highlighted by a jump in net income to $1.14 billion for Q1 2026, up from $879 million in Q1 2025. Total revenues expanded to $19.07 billion, pushing adjusted earnings to $1.59 billion. This growth followed a strategic reorganization completed in Q4 2025 that established MetLife Investment Management as a distinct reporting segment. Management fortified the capital structure in February 2026 by issuing $1 billion in 5.850% subordinated debentures while executing $755 million in stock repurchases during the first quarter.
Bulls will champion the robust top-line growth and disciplined expense targets, making the stock look attractively priced at 13.3x earnings as of May 7, 2026. Conversely, bears might argue that heavy reliance on variable investment income—projected to drop to between $220 million and $270 million in Q2 2026—leaves overall margins exposed to macroeconomic headwinds.
What to watch: profitability metrics for the newly separated MetLife Investment Management segment; trajectory of variable investment yields against the $1.6 billion full-year target.
Rev
$77.08B
FY2025
NI
$3.40B
FY2025
EPS$MET
$4.74
FY2025
OCF
$17.09B
FY2025
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
All MET Financial Metrics(49)
Income Statement
Balance Sheet
Cash Flow
Recent SEC Filings
METLIFE INC 8-K Report, Corporate Update (Aug 17, 2026)
MetLife, Inc. has filed an 8-K report on August 17, 2026, primarily announcing the declaration of several preferred stock dividends. These declarations include a quarterly dividend for Series A floating rate non-cumulative preferred stock, a semi-annual dividend for Series D fixed-to-floating rate non-cumulative preferred stock, and quarterly dividends for Series E and Series F non-cumulative preferred stocks. This filing directly communicates the company's commitment to its preferred shareholders and signals ongoing operational stability to manage these dividend obligations.
METLIFE INC 8-K Report, Financial Results (Aug 5, 2026)
MetLife, Inc. has filed an 8-K report on August 5, 2026, primarily to announce its financial results for the second quarter ended June 30, 2026. The report includes a press release detailing earnings, a supplementary financial report, and a fact sheet on assets under management (AUM). Additionally, MetLife's Board of Directors has approved a significant new $3.0 billion authorization for common stock repurchases, signaling a commitment to returning capital to shareholders. Investors should note that the detailed financial results and operational performance are contained within the furnished exhibits, such as the Earnings Release and Quarterly Financial Supplement. The inclusion of a new, substantial share buyback program suggests management's confidence in the company's financial health and valuation, potentially impacting future earnings per share and shareholder value.
METLIFE INC 8-K Report, Regulation FD Disclosure (Jun 29, 2026)
MetLife, Inc. (MET) has filed a Form 8-K to provide investors with preliminary insights into its variable investment income for the quarter ending June 30, 2026. The company estimates this income to be in the range of $220 million to $270 million (pre-tax). This preliminary figure offers a mid-quarter update ahead of the official earnings release scheduled for August 5, 2026, which will include the full quarterly financial supplement. This disclosure is important for investors tracking MetLife's diversified income streams, particularly those derived from private equity, real estate, and other funds, as well as prepayment fees. While this information is preliminary and unaudited, it provides a directional indication compared to the company's full-year 2026 guidance of approximately $1.6 billion (pre-tax) for variable investment income. Investors should exercise caution as actual results may differ materially, and this data should not replace the comprehensive financial statements.
METLIFE INC 8-K Report, Shareholder Vote Results (Jun 22, 2026)
MetLife, Inc. (MET) reported the results of its annual meeting of common shareholders held on June 16, 2026. The filing indicates strong shareholder support for the company's governance and executive compensation practices. All eleven director nominees were elected, and the appointment of Deloitte & Touche LLP as the independent auditor for 2026 was ratified with a substantial majority of votes. Additionally, shareholders provided advisory approval for the compensation of Named Executive Officers, signaling confidence in the company's leadership and compensation structure. These results suggest a stable shareholder base that is largely aligned with the current board and management. The overwhelming support for director elections and auditor ratification underscores a healthy corporate governance framework. Investors can view these outcomes as positive indicators of continuity and trust in MetLife's operational and strategic direction.
METLIFE INC 8-K Report, Corporate Update (May 15, 2026)
MetLife, Inc. (MET) has filed an 8-K report on May 15, 2026, primarily announcing the declaration of quarterly dividends on its various series of preferred stock. Investors focused on income generation or holding these preferred securities should note the specific dividend amounts declared for Series A, Series E, and Series F preferred stock. While this filing does not disclose material changes in financial performance or strategic direction, it confirms the company's ongoing commitment to returning capital to its preferred shareholders.
View all 8-K filings →